Considering immune checkpoints play vital roles in inhibiting the killing activity of effector T cells and immunotherapies that target immune checkpoints PD-1, PD-L1 and CTLA4 have achieved impressive success in various cancers, we further analyzed the expression levels of the three immune checkpoint molecules in the high- and low-risk subgroups. The gene discussed is CTLA4; the disease is cancer.